9 Feb 2015 10:17
4D pharma plc
(the 'Company' or '4D')
Result of general meeting
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed.
As a result, the placing announced on 21 January 2015 of 8,475,610 new ordinary shares at 410p per ordinary share to raise £34.75m, is conditional only on Admission which is expected to take place on 10 February 2015.
Following Admission, the Company's issued share capital will consist of 60,567,729 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that following Admission, the total number of voting rights in the Company will be 60,567,729.
For further information please contact:
4D | + 44 (0) 161 837 6205 |
Duncan Peyton, Chief Executive Officer
| |
Zeus Capital Limited - Nomad and Broker | |
Ross Andrews/Dan Bate | +44 (0) 161 831 1512 |
Dominic Wilson | +44 (0) 20 7533 7727 |